As payers struggle to cover high-priced pharmaceutical therapies in a year in which the first drug costing more than $1 million is expected to launch in the U.S., new payment models are emerging — including a “Netflix”-like subscription model in Louisiana for hepatitis C virus treatment — that could offer ways for patients to be treated without bankrupting the health care system.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.